ATTR Amyloidosis Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
ATTR Amyloidosis Treatment Market is segmented By Type (Hereditary ATTR Amyloidosis, Wild-type ATTR Amyloidosis), By Treatment (Pharmacological Therapies, Organ Transplantation, Supportive Care), By Route of Administration(Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
ATTR Amyloidosis Treatment Market Size
Market Size in USD
CAGR8.7%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 8.7% |
| Market Concentration | High |
| Major Players | Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Akcea Therapeutics, Inc. |
please let us know !
ATTR Amyloidosis Treatment Market Analysis
The ATTR amyloidosis treatment market is estimated to be valued at USD 3.8 Bn in 2024 and is expected to reach USD 6.82 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031. ATTR amyloidosis is a rare genetic disease with deposition of abnormal protein called amyloid in organs and tissues. Several treatment options and novel drug pipeline is expected to drive the growth of this market during the forecast period.